Begacestat is primarily investigated for its potential therapeutic applications in the treatment of Alzheimer's disease. It functions as a gamma-secretase modulator, targeting the amyloid precursor protein processing pathway. By selectively reducing the production of amyloid-beta 42, a peptide implicated in the formation of toxic plaques in the brain, Begacestat aims to slow or halt the progression of Alzheimer's. Its application is focused on improving cognitive function and memory in patients, offering a promising approach to managing this neurodegenerative disorder. Research continues to explore its efficacy, safety, and potential as a disease-modifying treatment.